Soligenix, Inc.

Reformulating An In-Clinic IV To At-Home Injection Puts Patients At The Center #CTCL #DefendYourHealth #SNGX @ClinicalLeader1 clinicalleader.com/doc/reformulat…

youtu.be/mRZ3PYPpMDk Biotech innovation continues to move forward. I recently spoke with Christopher J. Schaber, PhD, President and CEO of @Soligenix_Inc about their lead program, HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, and how they’re building a broader, diversified pipeline. With a second Phase 3 study now completed, the company is preparing for regulatory submissions and potential global commercialization. They’re also expanding into additional inflammatory and rare disease areas, supported by strategic partnerships and a multi-platform approach. It’s a compelling look at how Soligenix is positioning itself for both near-term milestones and long-term growth. #Biotech #Pharm

The Rare Disease Rubicon: Crossing The Chasm From Biotech To Bio-Commercial #defendyourhealth #SNGX talkmarkets.com/article/the-ra…

“Looking beyond science, it is execution and capital discipline that ultimately determine which biotech companies will survive” via @AsiaBioSpectrum #defendyourhealth #SNGX biospectrumasia.com/opinion/26/274…

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of #CTCL Published in Oncology and Therapy #defendyourhealth #SNGX ir.soligenix.com/2026-04-02-Pos…

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results #DefendYourHealth #SNGX ir.soligenix.com/2026-03-31-Sol…

Early recognition for Behcet’s disease underscores how rare inflammatory conditions are becoming part of the longevity conversation. vist.ly/4vv6q @Soligenix_Inc #longevity #inflammation #raredisease #immunology #geroscience

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease #defendyourhealth #SNGX ir.soligenix.com/2026-03-26-Sol…

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" #hybryte #CTCL #DefendYourHealth #SNGX ir.soligenix.com/2026-03-19-Sol…

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease #DefendYourHealth #SNGX ir.soligenix.com/2026-02-26-Sol…

Soligenix Details Recent Progress and Upcoming Milestones in Shareholder Update Letter #defendyourhealth #SNGX ir.soligenix.com/2026-02-12-Sol…

NetworkNewsBreaks – $SNGX SGX945 Shows Promise with Immune-Modulating Approach nnw.fm/5qTuE

MissionIRNewsBreaks – RiVax(R) Positions $SNGX in Growing Biodefense Preparedness Efforts ibn.fm/tb4QK

$SNGX Announces Positive Phase 2 Data for Rare Inflammatory Disease nnw.fm/o46FD

MissionIRNewsBreaks – $SNGX Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM) ibn.fm/6uNh7

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis #DefendYourHealth #SNGX ir.soligenix.com/2025-12-17-Sol…

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma #CTCL $SNGX ir.soligenix.com/2025-11-19-Sol…

InvestorNewsBreaks – $SNGX Eyes Dermatology Market with SGX302’s Encouraging Early Results ibn.fm/jJjjp

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma #CTCL #defendyourhealth ir.soligenix.com/2025-10-14-Sol…

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma #CTCL #DefendYourHealth #SNGX ir.soligenix.com/2025-10-07-Sol…